Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-010521
Filing Date
2025-02-07
Accepted
2025-02-07 16:01:19
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 16956
  Complete submission text file 0001104659-25-010521.txt   18692
Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund IV, L.P. (Filed by) CIK: 0001704131 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94841 | Film No.: 25601575
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)